How well do coverage surveys and programmatically reported mass drug administration coverage match? Results from 214 mass drug administration campaigns in 15 countries, 2008-2017.
Kathryn L ZoerhoffPamela S MbabaziKatherine GassJohn KraemerBrian B FullerLynsey BlairRoland BougmaAboulaye MeiteNebiyu NegussuBizuayehu GashawScott D NashNana-Kwadwo BiritwumJean Frantz LemoineHelena Ullyartha PangaribuanEksi WijayantiKarsor KollieClara Fabienne RasoamanamihajaLazarus JuziweloSquare MkwandaPradip RimalIssa GnandouBocar DiopAmeyo Monique DorkenooRachel BronzanEdridah Muheki TukahebwaFatima KaboleVioletta YevstigneyevaDonal BisanzioLauren CourtneyJoseph KoromaEgide EndayishimyeRichard ReithingerMargaret C BakerFiona M FlemingPublished in: BMJ global health (2023)
Programme managers must grapple with making decisions based on imperfect information, balancing needs for accuracy with cost and available capacity. The study shows that for many of the MDAs surveyed, based on the concordance with respect to reaching the minimum coverage thresholds, the routinely reported data were accurate enough to make programmatic decisions. Where coverage surveys do show a need to improve accuracy of routinely reported results, NTD programme managers should use various tools and approaches to strengthen data quality in order to use data for decision-making to achieve NTD control and elimination goals.